Eli Lilly will finalize its acquisition of Centessa Pharmaceuticals on June 24, 2026. The High Court of Justice of England and Wales has granted final approval for the transaction. Centessa shares are expected to conclude trading on the Nasdaq on June 23, 2026.
The deal carries a total valuation of approximately $7.8 billion. Lilly will pay $38.00 per share in cash. Shareholders will also receive a non-transferable contingent value right (CVR) worth up to $9.00 per share.
The acquisition bolsters Lilly’s neuroscience portfolio with new treatments for sleep-wake disorders. CVR payouts depend on achieving specific regulatory milestones for the lead drug candidate, cleminorexton. This closing follows the initial merger announcement made in March 2026.